Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec

Vancouver, British Columbia, June 15, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce deployment of its Marijuana Breath Test (“MBT”) products with a major industrial company operating in the heavy materials sector with significant workforce and operational footprint in Québec. The MBT is being utilized to support workplace safety programs, including post-incident and reasonable-cause testing protocols (see Figure 1). The delivery was completed through Montreal based Alco Prevention Canada.

This deployment reflects growing interest for breath-based THC testing solutions in heavy industry, where employers require timely and defensible indicators of recent cannabis use for safety-critical environments. Industrial operators, regulators, and insurers are increasingly seeking technologies that better align with real-time impairment risk and workplace decision-making.

Stéphane Maurais, General Manager, Alco Prevention Canada, stated, "We are extremely proud to partner with Cannabix to advance this innovative technology in the Canadian market. As organizations increasingly seek objective, non-invasive solutions to detect recent cannabis use. The Cannabix Marijuana Breath Test represents a significant advancement in workplace and public safety. At Alco Prevention Canada, our mission has remained unchanged for more than 37 years: to provide practical prevention tools that help save lives, reduce risk, and promote safer workplaces, roads, and communities."

Workplace Testing Clinics Face Growing Need for Recent‑Use THC Assessment

Industrial workplaces, particularly in sectors such as cement production, construction materials and manufacturing, present inherently higher safety risks. Employers in these sectors must balance evolving cannabis policies with strict safety, compliance, and liability requirements.

Traditional testing methods, including urine and oral fluid testing, can detect cannabis exposure long after “recent use” effects of THC have subsided. This extended duration creates challenges for industrial employers when making time-sensitive safety decisions which can increase the risk of disputes.

As a result, industrial organizations are seeking testing solutions that:

- Provide insight into recent cannabis use relevant to safety-sensitive roles

- Support post-incident and reasonable-cause investigations

- Reduce ambiguity associated with historical cannabis exposure

- Enhance defensibility of workplace testing policies and outcomes

Legacy urine and oral fluid tests can detect cannabis exposure days or weeks after use, making it difficult to provide results that meaningfully correlates with recent use. This gap creates operational, legal, and reputational risks for clinics when test results are challenged by employers, employees, unions, or legal counsel.

The Cannabix MBT offers employers a new non-invasive test to complement existing drug testing programs. Breath‑based THC testing provides several advantages including:

• Short detection window aligned with recent cannabis use
• Non‑invasive collection, improving subject compliance and experience with breath testing
• Objective, lab‑confirmed results using gold‑standard LC‑MS analysis
• Reduced exposure to legal challenges associated with historical positives

By integrating breath-based testing into their programs, industrial employers can enhance safety protocols while reducing uncertainty.

Strategic and Investor‑Focused Outlook

Cannabix believes breath-based THC testing can become a valuable tool across industrial sectors, particularly for deterrence, incident response, and fitness-for-duty applications. Continued deployments with major operators are expected to support broader adoption.